Galera Therapeutics Shares Surge As Citi Bumps Up Price Target To $20
Citi has raised the price target on Galera Therapeutics Inc (NASDAQ:GRTX) to $20 (suggesting 361% upside) from $11 and maintained a Buy rating. …
Citigroup Maintains Buy on Galera Therapeutics, Raises Price Target to $20
Citigroup analyst Yigal Nochomovitz maintains Galera Therapeutics (NASDAQ:GRTX) with a Buy and raises the price target from $11 to $20.
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news.
46 Biggest Movers From Yesterday
Gainers
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday.
36 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.
HC Wainwright & Co. Upgrades Galera Therapeutics to Buy, Announces $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Galera Therapeutics (NASDAQ:GRTX) from Neutral to Buy and announces $10 price target.
BTIG Upgrades Galera Therapeutics to Buy, Announces $15 Price Target
BTIG analyst Robert Hazlett upgrades Galera Therapeutics (NASDAQ:GRTX) from Neutral to Buy and announces $15 price target.
Why Galera Shares Are Surging More Than Double Today?
Galera Therapeutics Inc (NASDAQ:GRTX) has announced corrected results from its Phase 3 ROMAN trial of avasopasem for RT-induced severe oral mucositis…